USP7 promotes temozolomide resistance by stabilizing MGMT in glioblastoma
Abstract Glioblastoma (GBM), a World Health Organization (WHO) grade IV glioma, is one of the most lethal brain tumors, with a poor prognosis and limited treatment options. Temozolomide (TMZ), a first-line chemotherapeutic agent, often proves ineffective due to resistance and toxicity associated wit...
Saved in:
| Main Authors: | Jiabing Li, Xiaorong Feng, Zhaohui Liu, Yunfang Deng, Zhiming Sun, Bei Chen, Lihui Wu, Xiaolong Wang, Lin Miao, Liyuan Zeng, Lei Hu, Yuming He, Ying Sheng, Yue Liu, Yu Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-08-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-025-07969-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
GLUT3 enhances chemosensitivity in glioblastoma by transporting temozolomide and capecitabine
by: Honglin Diao, et al.
Published: (2025-08-01) -
Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
by: Supriya Mallick, et al.
Published: (2015-01-01) -
Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance
by: Jianlin Pu, et al.
Published: (2025-05-01) -
Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma
by: Justyna Magdalena Przystal, et al.
Published: (2019-02-01) -
Siramesine induced cell death of glioblastoma through inactivating the STAT3-MGMT signaling pathway
by: Xiaohang Cui, et al.
Published: (2025-07-01)